Selexis

Founded: 2001 • Age: 25 yrs Acquired By JSR Life Sciences
Developer of mammalian cell line for the production of recombinant proteins
Request Access

About Selexis

Selexis is a company founded in 2001 was acquired by JSR Life Sciences in June 2017.. Selexis operates in a competitive market with competitors including Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.

  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    JSR Life Sciences

    (Jun 14, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Selexis
Headcount 50-200
Employee Profiles 6
Employee Profiles
People
Delphine Cloarec
Cell Line Engineer
People
Mark Womack
CEO
People
Pierre-Alain Girod
Chief Scientific Officer
People
Roland Hoffmann-Hecht
Chief Business Officer

Unlock access to complete

Funding Insights of Selexis

  • Total Funding
  • Total Rounds 1
  • Last Round
  • First Round
  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2015 Amount Grant - Selexis Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Selexis

Selexis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include JSR Life Sciences. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Creates innovative technologies for raw materials in biopharmaceutical production.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Selexis

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Selexis

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Selexis Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Selexis

Selexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibody therapeutics are developed for immunology and oncology diseases.
domain founded_year HQ Location
Tumor-selective immunotherapies for cancer treatment are developed.
domain founded_year HQ Location
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
domain founded_year HQ Location
Biotherapeutics targeting cancer via interleukin-11 are developed.
domain founded_year HQ Location
Antibody-drug conjugates are developed for cancers and metabolic disorders.
domain founded_year HQ Location
Antibody therapeutics for anti-cancer immune responses are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Selexis

Frequently Asked Questions about Selexis

When was Selexis founded?

Selexis was founded in 2001 and raised its 1st funding round 14 years after it was founded.

What does Selexis do?

Selexis is developing mammalian (suspension-adapted CHO-K1) cell lines using its proprietary technology. Its SURE technology platform claims to facilitate the production of virtually any recombinant protein. It also provides drug discovery and cell line development services.

Who are the top competitors of Selexis?

Selexis's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.

Who are Selexis's investors?

Selexis has 1 investor. Key investors include JSR Life Sciences.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available